...
首页> 外文期刊>Health and Quality of Life Outcomes >Assessing patients’ acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community
【24h】

Assessing patients’ acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community

机译:评估患者接受药物治疗以揭示未满足的需求:使用患者在线社区的大型多疾病研究结果

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Patients with chronic conditions are required to take long-term treatments for their disease itself or to prevent any potential health risks. Measuring patient acceptance of their medication should help to better understand and predict patients' behavior toward treatment. This study aimed to describe the level of patient acceptance toward various long-term treatments in real life using an online patient community. This was an observational, cross-sectional study conducted through the French Carenity platform. All Carenity patient members were invited to complete an online questionnaire including the 25-item ACCEptance by the Patients of their Treatment (ACCEPT?) questionnaire. ACCEPT? measures patient acceptance toward their medication and includes one general acceptance dimension (Acceptance/General) and six treatment-attribute specific dimensions (scores 0-100; lowest to highest acceptance): Acceptance/Medication Inconvenience, Acceptance/Long-term Treatment, Acceptance/Regimen Constraints, Acceptance/Side effects, Acceptance/Effectiveness, and Acceptance/Numerous Medications. Patients included in the analysis were treated adults experiencing any chronic diseases and who responded to at least one ACCEPT? item. Among the 4193 patients included in the analysis, more than 270 chronic diseases were represented, amidst which 19 included more than 30 patients. Mean ACCEPT? Acceptance/General score for those 19 diseases were 61.2 (SD?=?31.9) for type 1 diabetes, 59.8 (SD?=?32.3) for asthma, 56.3 (SD?=?34.3) for hypertension, 52.0 (SD?=?32.2) for chronic obstructive pulmonary disease, 51.7 (SD?=?27.0) for epilepsy, 50.1 (SD?=?33.1) for bipolar disorder, 49.9 (SD?=?33.1) for type 2 diabetes, 48.6 (SD?=?31.6) for multiple sclerosis, 46.1 (SD?=?34.5) for Crohn's disease/ulcerative colitis, 44.3 (SD?=?31.5) for depression, 42.8 (SD?=?31.5) for lupus, 42.3 (SD?=?33.0) for arthrosis, 41.8 (SD?=?32.6) for Parkinson's disease, 40.5 (SD?=?32.2) for rheumatoid arthritis, 38.6 (SD?=?31.7) for breast cancer, 36.4 (SD?=?36.4) for myocardial infarction, 35.8 (SD?=?32.0) for ankylosing spondylitis, 34.1 (SD?=?32.3) for psoriasis, and 33.7 (SD?=?31.7) for fibromyalgia. This first of its kind study enabled ACCEPT? data to be collected in real life for a variety of chronic diseases. These data may help in evaluating and interpreting levels of acceptance in future studies and provide valuable insights about patient priorities and current unmet needs.
机译:慢性疾病的患者需要为其疾病本身服用长期治疗或防止任何潜在的健康风险。测量患者接受其药物应有助于更好地理解和预测患者对治疗的行为。本研究旨在使用在线患者社区描述在现实生活中对各种长期治疗的患者接受程度。这是通过法国肤色平台进行的观察性横截面研究。邀请所有肤色患者成员填写在线问卷,包括其治疗患者(接受?)问卷的25项接受。接受?措施患者对其药物的验收,包括一个普遍性验收维度(接受/一般)和六个治疗属性特定尺寸(分数0-100;最低到最高验收):验收/药物不便,接受/长期治疗,接受/方案约束,接受/副作用,接受/有效性和验收/众多药物。分析中包括的患者进行了经历任何慢性疾病的成年人,谁至少接受患者?物品。在分析中包含的4193名患者中,表示超过270个慢性疾病,其中19例包括超过30名患者。平均接受?对于患有1型糖尿病,59.8(SDα= 32.3),56.3(SD?= 34.3),52.0(SD? 32.2)对于慢性阻塞性肺病,51.7(SD?= 27.0)用于癫痫,50.1(SD?= 33.1)用于双极障碍,49.9(SD?= 33.1),适用于2型糖尿病,48.6(SD?=? 31.6)对于多发性硬化,46.1(SD?= 34.5),用于克罗恩病/溃疡性结肠炎,44.3(SD?= 31.5)抑郁症,42.8(SD?= 31.5),42.3(SD?=?33.0用于关节,41.8(SD?= 32.6)用于帕金森病,40.5(SD?= 32.2)用于类风湿性关节炎,38.6(SD?= 31.7)用于乳腺癌,36.4(SD?= 36.4)用于心肌的用于支链脊柱炎的35.8(SD?= 32.0),用于牛皮癣的34.1(SD?= 32.3),33.7(SD?= 31.7)用于纤维肌痛。第一个研究启用了它的研究吗?用于各种慢性疾病的现实生活中收集的数据。这些数据可能有助于评估和解释未来研究中的接受水平,并为患者优先事项和当前的未满足需求提供有价值的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号